Biomarkers for Amyotrophic Lateral Sclerosis in Active Duty Military (BALSAM)
Abstract
Purpose: To compare serum samples from individuals diagnosed with amyotrophic lateral sclerosis (ALS) to serum samples from matched individuals who did not develop ALS. In this study we aim to identify candidate serum biomarkers that are unique for ALS and identify a subset of diagnostic serum biomarkers for early detection of ALS prior to the appearance of overt symptoms. Scope: The significance of a positive identification of protein biomarkers for ALS is indisputably great. However to date no validated clinically relevant biomarkers have been found to allow a more specific diagnosis of ALS at an earlier stage. Previous efforts to identify ALS associated biomarkers have often focused on the identification of genes and proteins characteristic for familial ALS yet validated biomarkers for sporadic ALS which accounts for as much as 90-95% of all ALS cases have yet to be identified. Major Findings: None at this time. Progress: This study received USAMRMC HSSRB approval on 15 Jan 2007. The Durham VA and Univ. of Cincinnati IRB protocols have also been approved. Durham VA IRB began consenting the VA ALS registry members for this study. Model system 2-D gel and mass spectrometry studies have been conducted to develop improved techniques for biomarker identification.
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 22, 2008
- Accession Number
- ADA486649
Entities
People
- David E. Milhorn
Organizations
- University of Cincinnati